Chargement en cours...
Evaluation of Poly-Mechanistic Antiangiogenic Combinations to Enhance Cytotoxic Therapy Response in Pancreatic Cancer
Gemcitabine (Gem) has limited clinical benefits in pancreatic ductal adenocarcinoma (PDAC). The present study investigated combinations of gemcitabine with antiangiogenic agents of various mechanisms for PDAC, including bevacizumab (Bev), sunitinib (Su) and EMAP II. Cell proliferation and protein ex...
Enregistré dans:
| Auteurs principaux: | , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Public Library of Science
2012
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3377661/ https://ncbi.nlm.nih.gov/pubmed/22723862 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0038477 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|